Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

P. D. Le Coutre, F. J. Giles, A. Hochhaus, J. F. Apperley, G. J. Ossenkoppele, R. Blakesley, Y. Shou, N. J. Gallagher, M. Baccarani, J. Cortes, H. M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to or intolerant of imatinib. Patients with CML-AP (N=137) with at least 24 months of follow-up or who discontinued early were evaluated to determine the efficacy and tolerability of nilotinib. The majority (55%) of patients achieved a confirmed hematologic response, and 31% attained a confirmed complete hematologic response on nilotinib treatment. Overall, 32% of patients achieved major cytogenetic responses (MCyR), with most being complete cytogenetic responses. Responses were durable, with 66% of patients maintaining MCyR at 24 months. The estimated overall and progression-free survival rates at 24 months were 70% and 33%, respectively. Grade 3/4 neutropenia and thrombocytopenia were each observed in 42% of patients. Non-hematologic adverse events were mostly mild to moderate; the safety profile of nilotinib has not changed with longer follow-up. In all, 20 (15%) patients remained on study at data cutoff. In summary, nilotinib has a manageable safety profile, and can provide favorable long-term outcomes in the pretreated CML-AP patient population for whom treatment options are limited.

Original languageEnglish (US)
Pages (from-to)1189-1194
Number of pages6
JournalLeukemia
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Accelerated Phase
Cytogenetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Safety
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Neutropenia
Disease-Free Survival

Keywords

  • BCR-ABL
  • chronic myeloid leukemia (CML)
  • imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Le Coutre, P. D., Giles, F. J., Hochhaus, A., Apperley, J. F., Ossenkoppele, G. J., Blakesley, R., ... Kantarjian, H. M. (2012). Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia, 26(6), 1189-1194. https://doi.org/10.1038/leu.2011.323

Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance : 24-month follow-up results. / Le Coutre, P. D.; Giles, F. J.; Hochhaus, A.; Apperley, J. F.; Ossenkoppele, G. J.; Blakesley, R.; Shou, Y.; Gallagher, N. J.; Baccarani, M.; Cortes, J.; Kantarjian, H. M.

In: Leukemia, Vol. 26, No. 6, 01.06.2012, p. 1189-1194.

Research output: Contribution to journalArticle

Le Coutre, PD, Giles, FJ, Hochhaus, A, Apperley, JF, Ossenkoppele, GJ, Blakesley, R, Shou, Y, Gallagher, NJ, Baccarani, M, Cortes, J & Kantarjian, HM 2012, 'Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results', Leukemia, vol. 26, no. 6, pp. 1189-1194. https://doi.org/10.1038/leu.2011.323
Le Coutre, P. D. ; Giles, F. J. ; Hochhaus, A. ; Apperley, J. F. ; Ossenkoppele, G. J. ; Blakesley, R. ; Shou, Y. ; Gallagher, N. J. ; Baccarani, M. ; Cortes, J. ; Kantarjian, H. M. / Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance : 24-month follow-up results. In: Leukemia. 2012 ; Vol. 26, No. 6. pp. 1189-1194.
@article{99f6850c9dc948e68361f8f7a76dd91f,
title = "Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results",
abstract = "Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to or intolerant of imatinib. Patients with CML-AP (N=137) with at least 24 months of follow-up or who discontinued early were evaluated to determine the efficacy and tolerability of nilotinib. The majority (55{\%}) of patients achieved a confirmed hematologic response, and 31{\%} attained a confirmed complete hematologic response on nilotinib treatment. Overall, 32{\%} of patients achieved major cytogenetic responses (MCyR), with most being complete cytogenetic responses. Responses were durable, with 66{\%} of patients maintaining MCyR at 24 months. The estimated overall and progression-free survival rates at 24 months were 70{\%} and 33{\%}, respectively. Grade 3/4 neutropenia and thrombocytopenia were each observed in 42{\%} of patients. Non-hematologic adverse events were mostly mild to moderate; the safety profile of nilotinib has not changed with longer follow-up. In all, 20 (15{\%}) patients remained on study at data cutoff. In summary, nilotinib has a manageable safety profile, and can provide favorable long-term outcomes in the pretreated CML-AP patient population for whom treatment options are limited.",
keywords = "BCR-ABL, chronic myeloid leukemia (CML), imatinib, Nilotinib",
author = "{Le Coutre}, {P. D.} and Giles, {F. J.} and A. Hochhaus and Apperley, {J. F.} and Ossenkoppele, {G. J.} and R. Blakesley and Y. Shou and Gallagher, {N. J.} and M. Baccarani and J. Cortes and Kantarjian, {H. M.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1038/leu.2011.323",
language = "English (US)",
volume = "26",
pages = "1189--1194",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance

T2 - 24-month follow-up results

AU - Le Coutre, P. D.

AU - Giles, F. J.

AU - Hochhaus, A.

AU - Apperley, J. F.

AU - Ossenkoppele, G. J.

AU - Blakesley, R.

AU - Shou, Y.

AU - Gallagher, N. J.

AU - Baccarani, M.

AU - Cortes, J.

AU - Kantarjian, H. M.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to or intolerant of imatinib. Patients with CML-AP (N=137) with at least 24 months of follow-up or who discontinued early were evaluated to determine the efficacy and tolerability of nilotinib. The majority (55%) of patients achieved a confirmed hematologic response, and 31% attained a confirmed complete hematologic response on nilotinib treatment. Overall, 32% of patients achieved major cytogenetic responses (MCyR), with most being complete cytogenetic responses. Responses were durable, with 66% of patients maintaining MCyR at 24 months. The estimated overall and progression-free survival rates at 24 months were 70% and 33%, respectively. Grade 3/4 neutropenia and thrombocytopenia were each observed in 42% of patients. Non-hematologic adverse events were mostly mild to moderate; the safety profile of nilotinib has not changed with longer follow-up. In all, 20 (15%) patients remained on study at data cutoff. In summary, nilotinib has a manageable safety profile, and can provide favorable long-term outcomes in the pretreated CML-AP patient population for whom treatment options are limited.

AB - Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to or intolerant of imatinib. Patients with CML-AP (N=137) with at least 24 months of follow-up or who discontinued early were evaluated to determine the efficacy and tolerability of nilotinib. The majority (55%) of patients achieved a confirmed hematologic response, and 31% attained a confirmed complete hematologic response on nilotinib treatment. Overall, 32% of patients achieved major cytogenetic responses (MCyR), with most being complete cytogenetic responses. Responses were durable, with 66% of patients maintaining MCyR at 24 months. The estimated overall and progression-free survival rates at 24 months were 70% and 33%, respectively. Grade 3/4 neutropenia and thrombocytopenia were each observed in 42% of patients. Non-hematologic adverse events were mostly mild to moderate; the safety profile of nilotinib has not changed with longer follow-up. In all, 20 (15%) patients remained on study at data cutoff. In summary, nilotinib has a manageable safety profile, and can provide favorable long-term outcomes in the pretreated CML-AP patient population for whom treatment options are limited.

KW - BCR-ABL

KW - chronic myeloid leukemia (CML)

KW - imatinib

KW - Nilotinib

UR - http://www.scopus.com/inward/record.url?scp=84862028031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862028031&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.323

DO - 10.1038/leu.2011.323

M3 - Article

C2 - 22076466

AN - SCOPUS:84862028031

VL - 26

SP - 1189

EP - 1194

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -